8 completed, 6 terminated, 2 withdrawn, 1 recruiting. 16 Phase 2, 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 16 | Completed 6, Terminated 6, Withdrawn 2, Recruiting 1, Unknown 1 |
| Phase 1 | 6 | Completed 2, Terminated 2, Withdrawn 2 |
Follow Adenocarcinoma of the Esophagus: new trials by email Literature Review of Adenocarcinoma of the Esophagus trials Research Report on Adenocarcinoma of the Esophagus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Total Neoadjuvant Therapy for Lymph Node-positive Adenocarcinoma of the OESophagus and Oesophagogastric Junction FLOT-CROSS or CROSS-FLOT - Esophageal Cancer, Adenocarcinoma of the Esophagus | Phase 2 | Recruiting | Erasmus Medical Center | 216 | 2025-09-12 | 2025-12-22 |
| Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph Jction CA Monalizumab, Oxaliplatin, 5-Fluorouracil - Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction | Phase 1 / Phase 2 | Withdrawn | Jules Bordet Institute | 2017-07-20 | 2017-12-19 | |
| C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer c-Met inhibitor AMG 337, placebo, oxaliplatin - Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction | Phase 1 / Phase 2 | Withdrawn | Eastern Cooperative Oncology Group | 2015-03-06 | 2023-05-25 | |
| FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma oxaliplatin, leucovorin calcium, fluorouracil - Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction | Phase 2 | Unknown | Case Comprehensive Cancer Center | 63 | 2014-02-10 | 2024-01-08 |
| Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery cyclodextrin-based polymer-camptothecin CRLX101, Laboratory biomarker analysis, Pharmacological studies - Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction | Phase 2 | Completed | City of Hope Medical Center | 10 | 2012-11-01 | 2018-02-01 |
| Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer fluorouracil, leucovorin calcium, oxaliplatin - Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction | Phase 1 / Phase 2 | Completed | City of Hope Medical Center | 6 | 2012-02-01 | 2017-05-31 |
| Lapatinib With Carboplatin and Paclitaxel in Esophagus and Gastroesophageal Junction (GEJ) Carboplatin AUC, Paclitaxel, lapatinib - Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction | Phase 1 / Phase 2 | Terminated | Case Comprehensive Cancer Center | 13 | 2011-08-01 | 2019-03-19 |
| Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer bevacizumab, oxaliplatin, leucovorin calcium - Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction | Phase 2 | Completed | Fox Chase Cancer Center | 20 | 2011-04-27 | 2022-09-07 |
| Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy pralatrexate, docetaxel, fludeoxyglucose F 18 - Adenocarcinoma of the Esophagus, Adenocarcinomas of the Gastroesophageal Junction | Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 6 | 2010-07-01 | 2016-06-01 |
| Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer OncoGel (Paclitaxel gel), cisplatin, 5-FU - Esophageal Cancer, Adenocarcinoma of the Esophagus | Phase 2 | Terminated | Boston Scientific Corporation | 137 | 2008-01-01 | 2022-06-22 |
| Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydrochloride After Surgery in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction erlotinib hydrochloride, oxaliplatin, fluorouracil - Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction | Phase 1 | Completed | Wake Forest University Health Sciences | 9 | 2007-04-01 | 2018-07-02 |
| Nodal Status in Adenocarcinoma of the Esophagus an Cardia Subtotal esophagectomy and gastric pull up, Subtotal esophagectomy at the azygos vein, total gastrectomy - Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastric Cardia | Completed | University of Bologna | 194 | 2006-01-01 | 2012-07-25 | |
| FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction Cancer romidepsin, laboratory biomarker analysis - Adenocarcinoma of the Esophagus, Adenocarcinoma of the Stomach | Phase 2 | Terminated | National Cancer Institute (NCI) | 20 | 2004-10-01 | 2013-07-02 |
| 3-AP Plus Cisplatin in Treating Patients With Recurrent or Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction triapine, cisplatin - Adenocarcinoma of the Esophagus, Recurrent Esophageal Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 39 | 2004-01-01 | 2013-10-08 |
| Arsenic Trioxide in Treating Patients With Advanced Cancer of the Esophagus or Gastroesophageal Junction arsenic trioxide - Adenocarcinoma of the Esophagus, Stage III Esophageal Cancer | Phase 2 | Terminated | National Cancer Institute (NCI) | 50 | 2003-06-01 | 2013-01-23 |
| A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer oblimersen sodium, cisplatin, fluorouracil - Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 15 | 2003-06-01 | 2021-02-17 |
| Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer erlotinib hydrochloride, laboratory biomarker analysis - Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction | Phase 2 | Completed | National Cancer Institute (NCI) | 48 | 2002-06-01 | 2013-06-04 |
| Antineoplaston Therapy in Treating Patients With Cancer of the Esophagus Antineoplaston therapy (Atengenal + Astugenal) - Adenocarcinoma of the Esophagus | Phase 2 | Terminated | Burzynski Research Institute | 8 | 1996-05-30 | 2021-05-14 |
Adenocarcinoma Of Esophagus (18) · Esophageal Neoplasms (15) · Esophageal Squamous Cell Carcinoma (8) · Stomach Neoplasms (7) · Adenocarcinoma (1) · Carcinoma, Squamous Cell (1) · Gastrointestinal Neoplasms (1) · Neoplasms (1)
Digestive System Diseases (16) · Digestive System Neoplasms (16) · Esophageal Diseases (16) · Gastrointestinal Diseases (16) · Head and Neck Neoplasms (16) · Neoplasms by Site (16) · Gastrointestinal Neoplasms (15) · Neoplasms (15) · Carcinoma (8) · Neoplasms by Histologic Type (8) · Neoplasms, Glandular and Epithelial (8) · Neoplasms, Squamous Cell (8) · Carcinoma, Squamous Cell (7) · Stomach Diseases (7) · Esophageal Neoplasms (1)
Fluorouracil (8) · Oxaliplatin (6) · Leucovorin (4) · Cisplatin (3) · Radiotherapy (3) · 2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole (2) · Erlotinib Hydrochloride (2) · Fluorodeoxyglucose F18 (2) · Gene Expression Profiling (2) · Immunohistochemistry (2) · Magnetic Resonance Spectroscopy (2) · Paclitaxel (2) · Radiation (2) · Surgical Procedures, Operative (2) · 10-propargyl-10-deazaaminopterin (1)
National Cancer Institute (NCI) (5) · Case Comprehensive Cancer Center (2) · City of Hope Medical Center (2) · Boston Scientific Corporation (1) · Burzynski Research Institute (1) · Eastern Cooperative Oncology Group (1) · Erasmus Medical Center (1) · Fox Chase Cancer Center (1) · Jules Bordet Institute (1) · Ohio State University Comprehensive Cancer Center (1) · University of Bologna (1) · Wake Forest University Health Sciences (1)
United States (15) · Belgium (1) · Czechia (1) · India (1) · Italy (1) · Netherlands (1) · Poland (1)
Amelie Deleporte, Physician (1) · Andreas Kaubisch (1) · Ann Mauer (1) · Arthur Blackstock (1) · Bianca Mostert, MD, PhD (1) · Crystal Denlinger (1) · David Adelstein, MD (1) · David Ilson (1) · Herbert Hurwitz (1) · Jaffer Ajani (1) · Joseph Chao (1) · Kirk D Fowers, PhD (1) · Lakshmi Rajdev (1) · Michael McNamara, MD (1) · Neelesh Sharma, MD (1)
PMID 17462405, PMID 19738454, PMID 27890801, PMID 40340830
2016 (1), 2025 (1), N01CM17003 (1), N01CM62201 (1), N01CM62204 (1), N01CM62206 (1), P30CA006927 (1), U01CA099118 (1), U10CA180820 (1)